RESEARCH TRIANGLE PARK, N.C., March 1, 2011 /PRNewswire/ — Max
Neeman International has established a team of experts specialized
in carrying out rare disease trials in response to sponsor demand.
The team has the required expertise to develop innovative
approaches to optimize complex study design. Often strict
inclusion/exclusion criteria and data analysis for rare disease
studies create the greatest challenge for Biotech and Pharma that
the company’s expertise can address.
(Logo:
http://photos.prnewswire.com/prnh/20110105/CL25129LOGO)
Max Neeman is a leading CRO in India that has a focus on Rare
Disease Studies, in addition to other indications. Patient
enrollment for rare disease, complex global and multi-centric
trials is challenging because potential subjects are fewer in
number and widely dispersed. India has evolved into a
preferred destination for conducting such trials because of low
cost and faster patient recruitment supported by the country’s
diverse gene pool and vast population of 1.3B.
Rare diseases are frequently life-threatening or chronically
debilitating. However, drug development for these conditions has
been limited by relative unavailability of subjects for clinical
trials, as well as the high cost of investing in a novel
pharmaceutical agent with poor market potential.
Max Neeman International conducts India-based clinical research
services for clients across the globe delivering quality results
and exceptional customer service at a lower cost resulting in high
client satisfaction.
About Max Neeman International
Max Neeman International is one of the leading and largest CROs
in India and the clinical research arm of healthcare conglomerate,
Max India. Our specialty is that we offer services for the
successful conduct of Phase I-IV clinical and device trials for
small and mid-sized international and national Pharmaceutical,
Biotechnology, Medical Device and Nutr
‘/>”/>
